Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Down 24.7% in December

Kazia Therapeutics Limited (NASDAQ:KZIA) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 16,800 shares, a decline of 24.7% from the November 30th total of 22,300 shares. Based on an average daily trading volume, of 118,700 shares, the days-to-cover ratio is presently 0.1 days.

Kazia Therapeutics Trading Up 1.7 %

Shares of NASDAQ KZIA traded up $0.05 during mid-day trading on Friday, reaching $3.07. The company had a trading volume of 33,743 shares, compared to its average volume of 393,051. The firm has a 50 day simple moving average of $4.81 and a two-hundred day simple moving average of $4.13. Kazia Therapeutics has a 52-week low of $1.87 and a 52-week high of $15.80.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kazia Therapeutics stock. MAI Capital Management acquired a new stake in Kazia Therapeutics Limited (NASDAQ:KZIA) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned 51.66% of Kazia Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 30.89% of the company’s stock.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.